Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond.
FORUM trial
acute lymphoblastic leukaemia (All)
blinatumomab
children
chimeric antigen receptor T-cells (CAR T cells)
haematopoietic stem cell transplantation (HSCT)
infants
total body irradiation (TBI)
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
11
2021
accepted:
13
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
The ALL SCTped 2012 FORUM (For Omitting Radiation Under Majority age) trial compared outcomes for children ≥4 years of age transplanted for acute lymphoblastic leukaemia (ALL) who were randomised to myeloablation with a total body irradiation (TBI)-based or chemotherapy-based conditioning regimen. The TBI-based preparation was associated with a lower rate of relapse compared with chemoconditioning. Nevertheless, the age considered suitable for TBI was progressively raised over time to spare the most fragile youngest patients from irradiation-related complications. The best approach to use for children <4 years of age remains unclear. Children diagnosed with ALL in their first year of life, defined as infants, have a remarkably poorer prognosis compared with older children. This is largely explained by the biology of their ALL, with infants often carrying a
Identifiants
pubmed: 35281233
doi: 10.3389/fped.2022.807992
pmc: PMC8911028
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
807992Informations de copyright
Copyright © 2022 Balduzzi, Buechner, Ifversen, Dalle, Colita and Bierings.
Déclaration de conflit d'intérêts
JB has participated in advisory boards for Novartis, Janssen and Gilead, and speakers' bureaus for Novartis. AB has participated in advisory boards for Novartis and Amgen and speakers' bureau activities for Novartis, Amgen and Medac, and has received meeting support from Medac, Neovii and Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Blood Cancer. 2012 Nov;59(5):834-9
pubmed: 22488662
Blood Adv. 2021 Nov 15;:
pubmed: 34781362
Leukemia. 2011 Jan;25(1):181-4
pubmed: 20944674
Leuk Res. 2020 Jan;88:106283
pubmed: 31790983
Pediatr Blood Cancer. 2021 Jan;68(1):e28718
pubmed: 33098744
Br J Haematol. 2020 Mar;188(5):757-767
pubmed: 31725190
Leuk Lymphoma. 2019 Mar;60(3):639-648
pubmed: 30160568
JAMA. 2021 Mar 2;325(9):843-854
pubmed: 33651091
Blood Adv. 2019 Jul 9;3(13):1926-1929
pubmed: 31243002
Leukemia. 2021 Dec;35(12):3383-3393
pubmed: 34002027
Cancer. 2019 Jul 15;125(14):2474-2487
pubmed: 30920645
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Pediatr Blood Cancer. 2021 May;68(5):e28922
pubmed: 33638292
Br J Haematol. 2017 Oct;179(2):272-283
pubmed: 28771662
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Bone Marrow Transplant. 2021 Jan;56(1):257-266
pubmed: 32753706
Br J Haematol. 2020 Mar;188(6):945-961
pubmed: 31823355
Lancet Haematol. 2020 Nov;7(11):e816-e826
pubmed: 33091355
Biol Blood Marrow Transplant. 2017 Dec;23(12):2110-2117
pubmed: 28870778
Blood. 2010 Oct 14;116(15):2644-50
pubmed: 20592248
Front Oncol. 2021 Feb 26;11:637951
pubmed: 33718232
Bone Marrow Transplant. 2020 Oct;55(10):1996-2007
pubmed: 32203268
Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624
pubmed: 28087456
JAMA Pediatr. 2019 May 1;173(5):e190081
pubmed: 30882883
Pediatr Blood Cancer. 2014 Apr;61(4):712-6
pubmed: 24376191
Blood Cancer J. 2020 Jul 24;10(7):77
pubmed: 32709851
Leuk Res. 2020 Apr;91:106333
pubmed: 32109757
Nat Commun. 2016 Jul 27;7:12320
pubmed: 27460500
J Clin Oncol. 2019 Sep 1;37(25):2246-2256
pubmed: 31283407
J Clin Oncol. 2011 Jan 10;29(2):214-22
pubmed: 21135279
Blood. 2005 May 1;105(9):3749-56
pubmed: 15637143
Leukemia. 2021 Nov;35(11):3092-3100
pubmed: 33824464
Lancet. 2005 Aug 20-26;366(9486):635-42
pubmed: 16112299
Br J Haematol. 2021 Jun;193(6):1172-1177
pubmed: 33529389
JAMA. 2021 Mar 2;325(9):833-842
pubmed: 33651090
Pediatr Blood Cancer. 2020 Oct;67(10):e28624
pubmed: 32729239
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Blood. 2020 Apr 23;135(17):1501-1504
pubmed: 32043146
Bone Marrow Transplant. 2016 Nov;51(11):1482-1489
pubmed: 27348540
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
J Clin Oncol. 2020 Oct 1;38(28):3282-3293
pubmed: 32813610
J Clin Oncol. 1999 Jun;17(6):1838-46
pubmed: 10561223
Leukemia. 2007 Nov;21(11):2258-63
pubmed: 17690691
J Clin Oncol. 2021 Feb 1;39(4):295-307
pubmed: 33332189
Bone Marrow Transplant. 2020 Aug;55(8):1540-1551
pubmed: 32203263
Biol Blood Marrow Transplant. 2013 Feb;19(2):255-9
pubmed: 23041605
Biol Blood Marrow Transplant. 2017 Aug;23(8):1327-1334
pubmed: 28461213
Hematology Am Soc Hematol Educ Program. 2013;2013:601-4
pubmed: 24319238
Pediatr Blood Cancer. 2015 Mar;62(3):419-26
pubmed: 25399948
Leukemia. 2019 Apr;33(4):884-892
pubmed: 30267011
J Clin Med. 2021 Apr 29;10(9):
pubmed: 33946897
Biol Blood Marrow Transplant. 2019 Nov;25(11):2197-2210
pubmed: 31319153
J Clin Oncol. 2016 Dec 20;34(36):4381-4389
pubmed: 27998223
Biol Blood Marrow Transplant. 2018 Jul;24(7):1424-1431
pubmed: 29550628
Bone Marrow Transplant. 2008 Oct;42(8):515-22
pubmed: 18679374
Eur J Haematol. 2021 Apr;106(4):473-483
pubmed: 33320384
Lancet. 2007 Jul 21;370(9583):240-250
pubmed: 17658395
Int J Epidemiol. 2015 Feb;44(1):49-57
pubmed: 24639445
Blood. 2020 Oct 15;136(16):1813-1823
pubmed: 32845001
Pediatr Blood Cancer. 2015 Oct;62(10):1844-50
pubmed: 26053959
Leukemia. 2015 Feb;29(2):290-6
pubmed: 24888273
Biol Blood Marrow Transplant. 2019 Aug;25(8):1611-1620
pubmed: 30537550
Blood Adv. 2020 Nov 10;4(21):5414-5424
pubmed: 33147337
J Clin Oncol. 2015 Apr 10;33(11):1265-74
pubmed: 25753432